Polypodium Leucotomos - Cabozantinib Interaction Details

Interaction Details

Cabozantinib is classified as belonging to the following category: Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, Polypodium leucotomos might increase levels of drugs metabolized by CYP3A4.
In vitro and animal research suggests that Polypodium leucotomos can decrease the metabolism of midazolam by a mechanism possibly related to the inhibition of CYP3A4. However, a small study in humans suggests that taking Polypodium leucotomos with midazolam does not affect the metabolism of midazolam.

Interaction Rating

Minor

Likelihood of Occurrence

Unlikely

Interaction has been demonstrated in animal or in lab research but has been shown not to occur in humans.

References

Shinya K, Nishimura Y, Ryu K, et al. Short-term administration of Polypodium leucotomos extract does not inhibit CYP3A4-mediated metabolism of midazolam in healthy subjects: an open-label, two-period, fixed-sequence study. Int J Dermatol 2022.

Cabozantinib Overview

Cabozantinib (Cabometyx, Cometriq) is used to treat a number of conditions.
Cabozantinib (Cabometyx) is used:
- to treat advanced renal cell carcinoma (RCC; a type of cancer that begins in the cells of the kidneys).
- in combination with nivolumab (Opdivo) to treat advanced RCC in patients who have not yet received a treatment for RCC.
- to treat hepatocellular carcinoma (HCC; a type of liver cancer) in people who were previously treated with sorafenib (Nexafar).
- to treat a certain type of thyroid cancer in adults and children 12 years of age and older that has spread to nearby tissues or to other parts of the body and that has not responded to previous a treatment and cannot be treated with radioactive iodine.
Cabozantinib (Cometriq) is used:
- to treat a certain type of thyroid cancer that is getting worse and that has spread to other parts of the body.
Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.

See More Information Regarding Cabozantinib

Polypodium Leucotomos - More Interactions

Polypodium Leucotomos interacts with 621 drugs

Interaction Rating Key

These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.

Major	The combined use of these agents is strongly discouraged as serious side effects or other negative outcomes could occur.
Moderate	Use cautiously under the care of a healthcare professional or avoid this combination. A significant interaction or negative outcome could occur.
Minor	Be aware that there is a chance of an interaction. Watch for warning signs of a potential interaction.
Unknown	No interactions have been reported or no interaction data is currently available.